Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | ALK tyrosine kinase receptor | ||
Ligand | BDBM50396256 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_863887 (CHEMBL2176371) | ||
IC50 | 2±n/a nM | ||
Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
ALK tyrosine kinase receptor | |||
Name: | ALK tyrosine kinase receptor | ||
Synonyms: | ALK | ALK tyrosine kinase receptor (ALK) | ALK_HUMAN | Anaplastic lymphoma kinase | CD_antigen: CD246 | ||
Type: | Protein | ||
Mol. Mass.: | 176453.10 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9UM73 | ||
Residue: | 1620 | ||
Sequence: |
| ||
BDBM50396256 | |||
n/a | |||
Name | BDBM50396256 | ||
Synonyms: | CHEMBL2172328 | ||
Type | Small organic molecule | ||
Emp. Form. | C30H39N5O2 | ||
Mol. Mass. | 501.663 | ||
SMILES | CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccccc2)nc2ccc(CN3CCCCC3)cc12 |r,wU:9.12,6.5,(16.69,-49.6,;15.18,-49.28,;14.7,-47.81,;14.15,-50.42,;12.65,-50.11,;11.62,-51.25,;12.17,-48.64,;10.66,-48.32,;10.18,-46.87,;11.21,-45.72,;12.71,-46.03,;13.19,-47.49,;10.73,-44.26,;11.63,-43,;13.17,-42.99,;13.93,-41.65,;13.16,-40.33,;15.47,-41.64,;16.25,-42.97,;17.79,-42.96,;18.55,-41.63,;17.76,-40.29,;16.23,-40.31,;10.71,-41.75,;9.24,-42.24,;7.91,-41.48,;6.58,-42.25,;6.57,-43.79,;5.24,-44.56,;3.91,-43.79,;3.91,-42.25,;2.58,-41.48,;1.24,-42.24,;1.24,-43.78,;2.57,-44.56,;7.91,-44.56,;9.25,-43.79,)| | ||
Structure |